Forecast

There is no analyst data available for this company.

News Go to news feed

Sam Chun Dang Pharm shares surge after weight-loss pill deal with Daiichi Sankyo

Sam Chun Dang Pharm announced a joint development and commercialization agreement with Daiichi Sankyo for its oral weight-loss pill, triggering a more than 75% share rally this month and lifting chairman Yoon Dae-in into billionaire status. The company’s S-Pass technology converts injectables into pills and has attracted bullish analyst coverage; SCD is also pursuing a potentially $2 billion deal with Takeda for a long-acting injectable using its microsphere platform. SCD reported revenue growth and a 76% rise in net income year‑over‑year for the first nine months of 2025, supporting investor optimism. » More on forbes.com
Daiichi Sankyo launches phase‑3 study of ENHERTU with Pembrolizumab as first‑line treatment for HER2‑overexpressing NSCLC

Daiichi Sankyo and AstraZeneca have treated the first patient in the global phase‑3 DESTINY‑Lung06 study of ENHERTU in combination with Pembrolizumab as first‑line therapy for inoperable, locally advanced or metastatic HER2‑overexpressing NSCLC. The randomized trial is expected to enroll about 686 patients; the primary endpoint is progression‑free survival, with overall survival as an important secondary endpoint. The aim is to determine whether ENHERTU can replace platinum‑based chemotherapy in standard first‑line therapy and improve outcomes, as no HER2‑targeted first‑line drugs are currently approved for this patient group. » More on de.investing.com
FDA grants Daiichi Sankyo and Merck breakthrough therapy designation for Raludotatug Deruxtecan

The FDA has designated Raludotatug Deruxtecan from Daiichi Sankyo and Merck as a Breakthrough Therapy for the treatment of adult patients with platinum-resistant, CDH6-expressing ovarian, primary peritoneal, or fallopian tube cancer. The decision is based on data from a Phase 1 study and the ongoing Phase 2/3 study REJOICE-Ovarian01, whose Phase 3 portion has objective response rate and progression-free survival as primary endpoints. This is the first BTD for Raludotatug Deruxtecan and the second BTD since the collaboration between the two companies began. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Sankyo has already paid 0,24€ in dividends. The last payout was in June.

Financials

In the last quarter, Sankyo had revenue of 180,86M€ and net profit of 43,50M€

(EUR)	Jun 2026	YoY
Revenue	+180,86M	44,45%
Gross profit	+109,22M	45,38%
Net profit	+43,50M	57,74%
EBITDA	+60,53M	58,85%

Fundamentals

Metric	Value
Market capitalization	+2,10Mld€
Number of shares	197,51M
52-week high/low	+16,39€ - +8,22€
Dividend yield	+4,65%
Dividends TTM	+0,49€
Beta	0,21
P/E ratio	+10,65
PEG ratio	−0,35
P/B ratio	+1,57
P/S ratio	+2,48

Company profile

Sankyo Co., Ltd. produziert und verkauft Spielmaschinen und Kugellager-Versorgungssysteme in Japan. Das Unternehmen ist in den Segmenten Pachinko-Maschinen, Pachislot-Maschinen, Kugellager-Versorgungssysteme und Sonstige Geschäfte tätig. Das Geschäftssegment Pachinko-Maschinen produziert und verkauft Pachinko-Maschinen, Maschinenlehren sowie die dazugehörigen Teile. Das Geschäftssegment Pachinko-Maschinen produziert und vertreibt Pachislot-Maschinen und die dazugehörigen Teile. Das Geschäftssegment Kugellager-Versorgungssysteme produziert und verkauft Pachinko- und Pachislot-Kugelzuführungen, Kartensystem-Ausrüstung sowie Salonausrüstung und Peripheriegeräte. Das Segment Other Businesses beschäftigt sich mit der Vermietung von Immobilien und dem Verkauf von allgemeinen Formteilen. Das Unternehmen bietet auch mobile Content-Dienste an und betreibt einen Golfclub. Das Unternehmen vertreibt seine Produkte unter den Marken SANKYO und Bisty. Sankyo Co., Ltd. wurde 1960 gegründet und hat seinen Hauptsitz in Tokio, Japan.